|
US4474893A
(en)
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
|
US4501729A
(en)
|
1982-12-13 |
1985-02-26 |
Research Corporation |
Aerosolized amiloride treatment of retained pulmonary secretions
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
AU7966987A
(en)
|
1986-09-08 |
1988-04-07 |
Applied Biotechnology, Inc. |
Empty viral capsid vaccines
|
|
US4968603A
(en)
|
1986-12-31 |
1990-11-06 |
The Regents Of The University Of California |
Determination of status in neoplastic disease
|
|
EP0442926A1
(en)
|
1988-11-10 |
1991-08-28 |
Imperial Cancer Research Technology Limited |
Polypeptides
|
|
US5916563A
(en)
|
1988-11-14 |
1999-06-29 |
United States Of America |
Parvovirus protein presenting capsids
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
ES2026826A6
(es)
|
1991-03-26 |
1992-05-01 |
Ercros Sa |
Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
|
|
US5478745A
(en)
|
1992-12-04 |
1995-12-26 |
University Of Pittsburgh |
Recombinant viral vector system
|
|
US5869248A
(en)
|
1994-03-07 |
1999-02-09 |
Yale University |
Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
|
|
US5658785A
(en)
|
1994-06-06 |
1997-08-19 |
Children's Hospital, Inc. |
Adeno-associated virus materials and methods
|
|
US6204059B1
(en)
|
1994-06-30 |
2001-03-20 |
University Of Pittsburgh |
AAV capsid vehicles for molecular transfer
|
|
US5599706A
(en)
|
1994-09-23 |
1997-02-04 |
Stinchcomb; Dan T. |
Ribozymes targeted to apo(a) mRNA
|
|
US6040183A
(en)
|
1995-06-07 |
2000-03-21 |
University Of North Carloina At Chapel Hill |
Helper virus-free AAV production
|
|
US6093570A
(en)
|
1995-06-07 |
2000-07-25 |
The University Of North Carolina At Chapel Hill |
Helper virus-free AAV production
|
|
US6083702A
(en)
|
1995-12-15 |
2000-07-04 |
Intronn Holdings Llc |
Methods and compositions for use in spliceosome mediated RNA trans-splicing
|
|
EP0883344B2
(en)
|
1995-12-15 |
2010-06-09 |
VIRxSYS Corporation |
Therapeutic molecules generated by trans-splicing
|
|
AU4645697A
(en)
|
1996-09-11 |
1998-04-02 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Aav4 vector and uses thereof
|
|
US6156303A
(en)
|
1997-06-11 |
2000-12-05 |
University Of Washington |
Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
|
|
DE69939169D1
(de)
|
1998-05-28 |
2008-09-04 |
Us Gov Health & Human Serv |
Aav5 vektoren und deren verwendung
|
|
AU774706B2
(en)
|
1998-09-22 |
2004-07-08 |
Johns Hopkins University, The |
Methods for large-scale production of recombinant AAV vectors
|
|
DE69936104T2
(de)
|
1998-11-05 |
2008-01-17 |
The Trustees Of The University Of Pennsylvania |
Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
|
|
EP1135468B1
(en)
|
1998-11-10 |
2010-01-06 |
University Of North Carolina At Chapel Hill |
Virus vectors and methods of making and administering the same
|
|
JP2000325085A
(ja)
|
1999-05-21 |
2000-11-28 |
Masafumi Matsuo |
デュシェンヌ型筋ジストロフィー治療剤
|
|
US6653467B1
(en)
|
2000-04-26 |
2003-11-25 |
Jcr Pharmaceutical Co., Ltd. |
Medicament for treatment of Duchenne muscular dystrophy
|
|
US7465583B2
(en)
|
2000-06-01 |
2008-12-16 |
The University Of North Carolina At Chapel Hill |
Duplexed parvovirus vectors
|
|
AU6814901A
(en)
|
2000-06-01 |
2001-12-11 |
Univ North Carolina |
Methods and compounds for controlled release of recombinant parvovirus vectors
|
|
US6727355B2
(en)
|
2000-08-25 |
2004-04-27 |
Jcr Pharmaceuticals Co., Ltd. |
Pharmaceutical composition for treatment of Duchenne muscular dystrophy
|
|
US6623729B2
(en)
|
2001-07-09 |
2003-09-23 |
Korea Advanced Institute Of Science And Technology |
Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
|
|
ITRM20020253A1
(it)
|
2002-05-08 |
2003-11-10 |
Univ Roma |
Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
|
|
US20070026076A1
(en)
|
2003-02-24 |
2007-02-01 |
Tzyy-Choou Wu |
Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins
|
|
FR2874384B1
(fr)
|
2004-08-17 |
2010-07-30 |
Genethon |
Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
|
|
ES2926774T3
(es)
*
|
2013-03-15 |
2022-10-28 |
Univ North Carolina Chapel Hill |
Métodos y composiciones para vectores AAV de doble unión de glicano
|
|
KR102298579B1
(ko)
*
|
2013-05-21 |
2021-09-07 |
유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 |
캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
|
|
AU2015349759B2
(en)
*
|
2014-11-21 |
2022-01-06 |
The University Of North Carolina At Chapel Hill |
Aav vectors targeted to the central nervous system
|
|
WO2016126857A1
(en)
*
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
|
US10081659B2
(en)
*
|
2015-04-06 |
2018-09-25 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Adeno-associated vectors for enhanced transduction and reduced immunogenicity
|
|
AU2017337073A1
(en)
|
2016-09-30 |
2019-04-18 |
Baylor College Of Medicine |
Antibody based gene therapy with tissue-directed expression
|
|
WO2019213668A1
(en)
*
|
2018-05-04 |
2019-11-07 |
Oregon Health & Science University |
Human anti-aav2 capsid polyclonal antibody epitopes
|
|
JP7428664B2
(ja)
*
|
2018-06-12 |
2024-02-06 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
合成肝臓指向性アデノ随伴ウイルスカプシドおよびその使用
|
|
CN120349985A
(zh)
*
|
2018-10-12 |
2025-07-22 |
建新公司 |
通过肝导向基因替代疗法治疗严重pku的改良的人pah的产生
|